ArticleCrohn's & colitis 3602025
Impact of Precision-Guided Dosing on Clinical Decision-Making and Health Care Utilization in Inflammatory Bowel Disease: A Retrospective Pretest/Posttest Real-World Study.
Article in Crohn's & colitis 360, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biologics in Kidney Transplantation: Why and How Should We Personalize Their Dosage?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Precision-guided dosing (PGD) is a personalized tool that optimizes clinical decision-making in the treatment of inflammatory bowel disease (IBD) with infliximab (IFX) and its biosimilars. PGD employs nonlinear mixed-effect models using patient-specific pharmacokinetic parameters to predict infliximab trough concentrations without the need to wait until the actual trough measurement. This approach calculates patient-specific clearance (CL) and provides tailored IFX dosing and administration intervals aimed at achieving target trough levels. Implementing PGD can enhance treatment outcomes in IBD patients and may potentially reduce healthcare expenditures. Methods: We conducted a multicenter, retrospective study as a follow up to our previous clinical experience program (CEP). We aimed to evaluate the impact of PGD on clinical decision-making, patient outcomes, healthcare utilization, and expenditures. Treatment decisions included: IFX dose intensification, reduction, discontinuation, or continuation. Disease activity and healthcare resource utilization and costs in the 12 months pre- and post-test were compared. Disease activity was measured using the physician global assessment (PGA) as follows: remission (0), mild (1), moderate (2), and severe (3). Costs were calculated based on modeling pre-established literature data. Results: Analysis of data from 82 patients across 7 states and Puerto Rico showed that PGD-driven therapeutic decision making led to IFX treatment intensification (27%) or discontinuation (7%) in patients with low forecasted trough IFX concentrations, high clearance, and presence of antidrug antibody. Conversely, IFX dosage was reduced (18%) or unchanged (48%) for patients with high IFX concentrations and low clearance. There was a significant association between forecasted trough IFX levels and treatment modifications ( Conclusions: HCPs used the PGD test to guide treatment decisions. PGD-driven optimization of IFX therapy led to improved patient outcomes, lower healthcare utilization, and cost savings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.